title: [Comparison of in vitro and in vivo methods of evaluation of the efficacy of influenza virus hemagglutinin inhibitors].
abstract: One of the problem in the selection of the most effective antiviral preparations with a broad spectrum of antiviral protective activity, is the "continuity" of assays of different level of complexity so, that the most effective antiviral therapeutic, selected by in vitro assays would be the most effective in vivo. Comparative study of the efficacy of the influenza virus inhibitor in the assays of inhibition of virus binding with fetuin, inhibition of infectious focus forming units in MDCK cells, inhibition of virus yield in infected MDCK cells, and inhibition of influenza virus infectivity in mice infected by viral aerosol are presented. The value of 50% inhibiting concentration IC50 for the pare "influenza virus strain A/NIB/23/89-MA-inhibitor tetra-Aca6-6'SLN" corresponded to 6-10 microM and was invariant for three different tests--in vitro assay of inhibition of virus binding with fetuin, inhibition of yield in infected MDCK cell culture, and inhibition of virus infectivity in mice, but not for the assay of inhibition of infectious focus forming units in cell culture.
authors.forename: E P
authors.initials: EP
authors.lastname: Goncharova
authors.forename: L E
authors.initials: LE
authors.lastname: Bylychev
authors.forename: S V
authors.initials: SV
authors.lastname: Rak
authors.forename: O G
authors.initials: OG
authors.lastname: P'iankova
authors.forename: V D
authors.initials: VD
authors.lastname: Poryvaev
authors.forename: A B
authors.initials: AB
authors.lastname: Ryzhikov
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000956:Antigens, Viral / Q000378:metabolism; D000998:Antiviral Agents / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D002460:Cell Line; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000378:metabolism*; D009980:Influenza A virus / Q000254:growth & development / Q000378:metabolism* / Q000472:pathogenicity; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests / Q000379:methods*; D009844:Oligosaccharides / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D009976:Orthomyxoviridae Infections / Q000517:prevention & control / Q000821:virology*; D011485:Protein Binding / Q000187:drug effects; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D000956:Antigens, Viral; D000998:Antiviral Agents; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D009844:Oligosaccharides; D000509:alpha-Fetoproteins; C109963:hemagglutinin, avian influenza A virus; C016735:sialooligosaccharides